These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 28600574)

  • 1. Promoter hypermethylation inactivates CDKN2A, CDKN2B and RASSF1A genes in sporadic parathyroid adenomas.
    Arya AK; Bhadada SK; Singh P; Sachdeva N; Saikia UN; Dahiya D; Behera A; Bhansali A; Rao SD
    Sci Rep; 2017 Jun; 7(1):3123. PubMed ID: 28600574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline and somatic mutations in cyclin-dependent kinase inhibitor genes CDKN1A, CDKN2B, and CDKN2C in sporadic parathyroid adenomas.
    Costa-Guda J; Soong CP; Parekh VI; Agarwal SK; Arnold A
    Horm Cancer; 2013 Oct; 4(5):301-7. PubMed ID: 23715670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent promoter hypermethylation of the APC and RASSF1A tumour suppressors in parathyroid tumours.
    Juhlin CC; Kiss NB; Villablanca A; Haglund F; Nordenström J; Höög A; Larsson C
    PLoS One; 2010 Mar; 5(3):e9472. PubMed ID: 20208994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes.
    Guney S; Jardin F; Bertrand P; Mareschal S; Parmentier F; Picquenot JM; Tilly H; Bastard C
    Genes Chromosomes Cancer; 2012 Sep; 51(9):858-67. PubMed ID: 22619049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global and gene-specific promoter methylation analysis in primary hyperparathyroidism.
    Sulaiman L; Juhlin CC; Nilsson IL; Fotouhi O; Larsson C; Hashemi J
    Epigenetics; 2013 Jun; 8(6):646-55. PubMed ID: 23764768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of DNA (Cytosine-5)-Methyltransferase 1 (DNMT1) And DNA (Cytosine-5)-Methyltransferase 3A (DNMT3A) Is Associated with Aggressive Behavior and Hypermethylation of Tumor Suppressor Genes in Human Pituitary Adenomas.
    Ma HS; Wang EL; Xu WF; Yamada S; Yoshimoto K; Qian ZR; Shi L; Liu LL; Li XH
    Med Sci Monit; 2018 Jul; 24():4841-4850. PubMed ID: 30002361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas.
    Kirsch M; Mörz M; Pinzer T; Schackert HK; Schackert G
    Genes Chromosomes Cancer; 2009 Feb; 48(2):143-54. PubMed ID: 18973139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic trioxide inhibits DNA methyltransferase and restores expression of methylation-silenced CDKN2B/CDKN2A genes in human hematologic malignant cells.
    Fu HY; Shen JZ; Wu Y; Shen SF; Zhou HR; Fan LP
    Oncol Rep; 2010 Aug; 24(2):335-43. PubMed ID: 20596618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysregulated mitogen-activated protein kinase pathway mediated cell cycle disruption in sporadic parathyroid tumors.
    Arya AK; Singh P; Saikia UN; Sachdeva N; Dahiya D; Behera A; Rao SD; Bhadada SK
    J Endocrinol Invest; 2020 Feb; 43(2):247-253. PubMed ID: 31535356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of CDKN2A, CDKN2B, CDKN2C, and cyclin Ds gene status in hepatoblastoma.
    Iolascon A; Giordani L; Moretti A; Basso G; Borriello A; Della Ragione F
    Hepatology; 1998 Apr; 27(4):989-95. PubMed ID: 9537438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
    Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
    Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours.
    Rousseau E; Ruchoux MM; Scaravilli F; Chapon F; Vinchon M; De Smet C; Godfraind C; Vikkula M
    Neuropathol Appl Neurobiol; 2003 Dec; 29(6):574-83. PubMed ID: 14636164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of RASSF1A tumor suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas.
    Qian ZR; Sano T; Yoshimoto K; Yamada S; Ishizuka A; Mizusawa N; Horiguchi H; Hirokawa M; Asa SL
    Lab Invest; 2005 Apr; 85(4):464-73. PubMed ID: 15711568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of CDKN2C/p18, CDKN1B/p27 and CDKN2B/p15 mRNA expression, and CpG methylation status in sporadic and MEN1-associated pancreatic endocrine tumours.
    Lindberg D; Akerström G; Westin G
    Clin Endocrinol (Oxf); 2008 Feb; 68(2):271-7. PubMed ID: 17803708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular pathogenesis of primary hyperparathyroidism.
    Arnold A; Shattuck TM; Mallya SM; Krebs LJ; Costa J; Gallagher J; Wild Y; Saucier K
    J Bone Miner Res; 2002 Nov; 17 Suppl 2():N30-6. PubMed ID: 12412775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parathyroid tumor suppressor on 1p: analysis of the p18 cyclin-dependent kinase inhibitor gene as a candidate.
    Tahara H; Smith AP; Gaz RD; Zariwala M; Xiong Y; Arnold A
    J Bone Miner Res; 1997 Sep; 12(9):1330-4. PubMed ID: 9286748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients.
    Spitzwieser M; Entfellner E; Werner B; Pulverer W; Pfeiler G; Hacker S; Cichna-Markl M
    BMC Cancer; 2017 Apr; 17(1):260. PubMed ID: 28403857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural and functional analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in neuroblastoma.
    Iolascon A; Giordani L; Moretti A; Tonini GP; Lo Cunsolo C; Mastropietro S; Borriello A; Ragione FD
    Pediatr Res; 1998 Jan; 43(1):139-44. PubMed ID: 9432125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced Calcium Sensing Receptor (CaSR) Expression Is Epigenetically Deregulated in Parathyroid Adenomas.
    Singh P; Bhadada SK; Dahiya D; Arya AK; Saikia UN; Sachdeva N; Kaur J; Brandi ML; Rao SD
    J Clin Endocrinol Metab; 2020 Sep; 105(9):3015-24. PubMed ID: 32609827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and prognostic effects of
    Xia L; Zhang W; Gao L
    Biomarkers; 2019 Nov; 24(7):700-711. PubMed ID: 31382782
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.